Immune and gene-expression profiling in estrogen receptor low and negative early breast cancerDavide Massa, Maria Vittoria Dieci, Carlo Pescia et al.|JNCI Journal of the National Cancer Institute|2024Cited by 32
1MO Tumor immune microenvironment in ER-negative vs ER-low, HER2-neg breast cancerDavide Massa, Maria Vittoria Dieci, Riccardo Lobefaro et al.|ESMO Open|2023Cited by 4
Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC TrialFederica Miglietta, Maria Vittoria Dieci, Manon de Graaf et al.|Clinical Cancer Research|2025Cited by 1
178P PD-L1 expression in ER-low versus triple-negative (TN) advanced breast cancer (aBC), and according to phenotypic evolution from primary to recurrent diseaseFederica Miglietta, Maria Vittoria Dieci, Lorenzo Nicolè et al.|Annals of Oncology|2024Cited by 0
Prognostic role of estrogen receptor (ER) expression in breast cancer (BC) metastases and its dynamics from primary to metastatic disease: Results from a large multicentric cohort of patients with phenotypically stable ER+(≥10%)/HER2- BC.Federica Miglietta, Maria Vittoria Dieci, Andrea Botticelli et al.|Journal of Clinical Oncology|2025Cited by 0